{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:25Z","timestamp":1787027905580,"version":"build-2736575974"},"reference-count":16,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Christie Charity"},{"name":"Syncona Foundation"},{"name":"The Infrastructure Industry Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Salivary gland cancers (SGC) are rare tumours with limited availability of systemic therapies. Some SGC subtypes overexpress HER2, and this represents a potential therapeutic target, but the evidence base is limited. This study sought to analyse real-world data on the efficacy of HER2-directed therapies in SGC. This is a retrospective observational study using anonymised data from commercial compassionate-use access registrations and a privately funded pharmacy prescribing register. Treatment duration was defined as the time from drug initiation to treatment discontinuation. Kaplan\u2013Meier analysis of treatment duration was performed using R for Windows (v4.3.2). A case report is also provided of an exceptional responder. Eighteen patients were identified who received HER2-directed therapies for HER2-positive recurrent\/metastatic SGC, and complete data on treatment duration was available for 15\/18. Histology was salivary duct carcinoma in 13\/18 patients, adenocarcinoma NOS in 4\/18, and carcinoma ex pleomorphic adenoma in 1\/18. The median treatment duration was 8.3 months (95% CI: 6.41-not reached), and the range was 1.0\u201347.0 months. Choice of HER2-directed therapy varied, with ado-trastuzumab emtasine being the most common (9\/18). At the time of analysis, HER2-directed therapy was ongoing for 9\/15, discontinued due to disease progression for 4\/15, discontinued due to toxicity for 1\/15, and 1\/15 was discontinued for an unspecified reason. An exceptional responder experienced a complete response with a treatment duration of 47.0 months. These real-world data are comparable to the median PFS observed with HER2-directed therapies in phase II trials and support the use of HER2-directed therapies in this group.<\/jats:p>","DOI":"10.3390\/curroncol31090419","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T09:16:10Z","timestamp":1727428570000},"page":"5652-5661","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6389-6276","authenticated-orcid":false,"given":"Joseph Edward","family":"Haigh","sequence":"first","affiliation":[{"name":"The Christie NHS Foundation Trust, Wilmslow Road Manchester, Manchester M20 4BX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Patel","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Wilmslow Road Manchester, Manchester M20 4BX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Rack","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Wilmslow Road Manchester, Manchester M20 4BX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Jim\u00e9nez-Labaig","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK"},{"name":"Department of Medicine, Universidad Aut\u00f3noma de Barcelona, Pla\u00e7a C\u00edvica, Bellaterra, 08193 Barcelona, Spain"},{"name":"The Institute of Cancer Research, Division of Radiotherapy and Imaging, 123 Old Brompton Road, London SW7 3RP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9027-2792","authenticated-orcid":false,"given":"Guy","family":"Betts","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust, Oxford Road, Manchester M13 9WL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Joseph","family":"Harrington","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK"},{"name":"The Institute of Cancer Research, Division of Radiotherapy and Imaging, 123 Old Brompton Road, London SW7 3RP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Metcalf","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Wilmslow Road Manchester, Manchester M20 4BX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of Salivary Gland Malignancy: ASCO Guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"JCO"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100602","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO\u2014European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"7","author":"Poorten","year":"2022","journal-title":"ESMO Open"},{"key":"ref_3","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024, August 21). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.who.int\/today."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","article-title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies","volume":"28","author":"Ross","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rack, S., Feeney, L., Hapuarachi, B., Adderley, H., Woodhouse, L., Betts, G., Burghel, G.J., Harrington, K.J., and Metcalf, R. (2022). Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer. Cancers, 14.","DOI":"10.3390\/cancers14051133"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Egebjerg, K., Harwood, C.D., Woller, N.C., Kristensen, C.A., and Mau-S\u00f8rensen, M. (2021). HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.693394"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"JCO"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II Trial of Trastuzumab and Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2\u2013Positive Salivary Duct Carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"JCO"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: Results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_10","unstructured":"R Core Team (2023). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org."},{"key":"ref_11","unstructured":"Sjoberg, D., Baillie, M., Fruechtenicht, C., Haesendonckx, S., and Treis, T. (2024, September 19). ggsurvfit: Flexible Time-to-Event Figures. R package Version 1.0.0. Available online: https:\/\/CRAN.R-project.org\/package=ggsurvfit."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wickham, H. (2016). ggplot2: Elegant Graphics for Data Analysis, Springer-Verlag. Available online: https:\/\/ggplot2.tidyverse.org.","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhu, K., Yang, X., Tai, H., Zhong, X., Luo, T., and Zheng, H. (2024). HER2-targeted therapies in cancer: A systematic review. Biomark Res., 12.","DOI":"10.1186\/s40364-024-00565-1"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: Advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/419\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:01:21Z","timestamp":1760112081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["curroncol31090419"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31090419","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,21]]}}}